Latest News for: dll3

Edit

Next-generation anti-DLL3 radiopharmaceuticals targeting high-grade neuroendocrine lung and prostate cancers

PNAS 02 Feb 2026
.
Edit

Molecular Partners Announces Presentation of First Imaging and Dosimetry Data of DLL3-Targeting Radiotherapy MP0712 in ...

Nasdaq Globe Newswire 02 Feb 2026
MOLN), a clinical-stage biotech company developing a novel class of custom-built protein drugs known as DARPin therapeutics ...
Edit

Molecular Partners Announces Presentation of First Imaging and Dosimetry Data of DLL3-Targeting Radiotherapy MP0712 in Patients at TWC 2026 (Form 6-K) (Molecular Partners AG)

Public Technologies 02 Feb 2026
"I am highly encouraged by the data generated in my group suggesting a favorable distribution profile of MP0712, a DLL3-targeted radiopharmaceutical for patients with SCLC and NEC cancers," said Dr.
Edit

TellDx-Enabled Circulating Tumor Cell Analysis Predicts Response to DLL3-Targeted Therapy in Small Cell Lung Cancer

Nasdaq Globe Newswire 14 Jan 2026
-- Study Results Support the use of TellDx to Personalize Cancer Care Management – ... .
Edit

DLL3-Targeted Immunotherapy Competitor Analysis Report 2025: The Field Still is in Mid-stage Clinical Development Without ...

Nasdaq Globe Newswire 27 Nov 2025
DLL3-targeted immunotherapies present promising opportunities in treating small cell lung cancer (SCLC) and neuroendocrine carcinomas (NECs) due ...
Edit

Molecular Partners Presents New Data for DLL3 Targeting Radiotherapy MP0712 at TRP Summit Europe 2025, ...

Nasdaq Globe Newswire 12 Nov 2025
... new data on MP0712, its lead Radio-DARPin targeting DLL3, at the Targeted Radiopharmaceuticals (TRP) Summit Europe, highlighting first encouraging human images and supporting mechanism of action data.
Edit

Molecular Partners Presents New Data for DLL3 Targeting Radiotherapy MP0712 at TRP Summit Europe 2025, Highlighting Initial Human Images and Mechanism of Action (Form 6-K) (Molecular Partners AG)

Public Technologies 12 Nov 2025
Molecular Partners Presents New Data for DLL3 Targeting Radiotherapy MP0712 ... MP0712 Radio-DARPin leverages rapid internalization & replenishment of DLL3 to achieve high accumulation in tumor cells.
  • 1

Article Search

tools
×
×
×
×